Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice

Antimicrob Agents Chemother. 2000 Mar;44(3):783-6. doi: 10.1128/AAC.44.3.783-786.2000.

Abstract

Oral administration of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652), a nucleoside analog structurally similar to lamivudine (3TC), caused dose-dependent inhibition of viral replication in SCID-hu Thy/Liv mice infected with human immunodeficiency virus type 1 NL4-3 and with an NL4-3 clone containing the M184V mutation in reverse transcriptase that confers resistance to 3TC. These experiments demonstrate the utility of this mouse model for evaluating drug resistance and for performing direct comparisons between antiviral compounds in vivo.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Anti-HIV Agents / pharmacology*
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology
  • Disease Models, Animal
  • Drug Resistance, Microbial
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV Reverse Transcriptase / genetics
  • HIV-1 / drug effects*
  • HIV-1 / physiology
  • Humans
  • Lamivudine / pharmacology*
  • Leukocytes, Mononuclear / virology
  • Mice
  • Mice, SCID
  • Reverse Transcriptase Inhibitors / pharmacology
  • Thionucleosides / pharmacology*
  • Virus Replication / drug effects

Substances

  • 2'-deoxy-3'-oxa-thiocytidine
  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Thionucleosides
  • Deoxycytidine
  • Lamivudine
  • HIV Reverse Transcriptase